Disease-level drug approval forecasting from trial-agnostic public data

Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before test…